Zile Michael R, Baicu Catalin F, Ikonomidis John S, Stroud Robert E, Nietert Paul J, Bradshaw Amy D, Slater Rebecca, Palmer Bradley M, Van Buren Peter, Meyer Markus, Redfield Margaret M, Bull David A, Granzier Henk L, LeWinter Martin M
From Division of Cardiology, Department of Medicine, Medical University of South Carolina, and RHJ Department of Veterans Affairs Medical Center, Charleston, SC (M.R.Z., C.F.B., A.D.B.); Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, and RHJ Department of Veterans Affairs Medical Center, Charleston, SC (J.S.I., R.E.S.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC (P.J.N.); Department of Cellular and Molecular Medicine, University of Arizona, Tucson (R.S., H.L.G.); Cardiology Unit, Department of Medicine, University of Vermont, Burlington (B.M.P., P.V.B., M.M., M.M.L.W.); Department of Molecular Physiology and Biophysics, University of Vermont, Burlington (B.M.P., P.V.B., M.M.L.W.); Division of Cardiology, Mayo Clinic, Rochester, MN (M.M.R.); and Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City (D.A.B.).
Circulation. 2015 Apr 7;131(14):1247-59. doi: 10.1161/CIRCULATIONAHA.114.013215. Epub 2015 Jan 30.
The purpose of this study was to determine whether patients with heart failure and a preserved ejection fraction (HFpEF) have an increase in passive myocardial stiffness and the extent to which discovered changes depend on changes in extracellular matrix fibrillar collagen and cardiomyocyte titin.
Seventy patients undergoing coronary artery bypass grafting underwent an echocardiogram, plasma biomarker determination, and intraoperative left ventricular epicardial anterior wall biopsy. Patients were divided into 3 groups: referent control (n=17, no hypertension or diabetes mellitus), hypertension (HTN) without (-) HFpEF (n=31), and HTN with (+) HFpEF (n=22). One or more of the following studies were performed on the biopsies: passive stiffness measurements to determine total, collagen-dependent and titin-dependent stiffness (differential extraction assay), collagen assays (biochemistry or histology), or titin isoform and phosphorylation assays. In comparison with controls, patients with HTN(-)HFpEF had no change in left ventricular end-diastolic pressure, myocardial passive stiffness, collagen, or titin phosphorylation but had an increase in biomarkers of inflammation (C-reactive protein, soluble ST2, tissue inhibitor of metalloproteinase 1). In comparison with both control and HTN(-)HFpEF, patients with HTN(+)HFpEF had increased left ventricular end-diastolic pressure, left atrial volume, N-terminal propeptide of brain natriuretic peptide, total, collagen-dependent, and titin-dependent stiffness, insoluble collagen, increased titin phosphorylation on PEVK S11878(S26), reduced phosphorylation on N2B S4185(S469), and increased biomarkers of inflammation.
Hypertension in the absence of HFpEF did not alter passive myocardial stiffness. Patients with HTN(+)HFpEF had a significant increase in passive myocardial stiffness; collagen-dependent and titin-dependent stiffness were increased. These data suggest that the development of HFpEF depends on changes in both collagen and titin homeostasis.
本研究旨在确定射血分数保留的心力衰竭(HFpEF)患者的被动心肌僵硬度是否增加,以及所发现的变化在多大程度上取决于细胞外基质纤维状胶原蛋白和心肌肌联蛋白的变化。
70例行冠状动脉旁路移植术的患者接受了超声心动图检查、血浆生物标志物测定及术中左心室心外膜前壁活检。患者分为3组:对照参考组(n = 17,无高血压或糖尿病)、无(-)HFpEF的高血压(HTN)组(n = 31)和有(+)HFpEF的HTN组(n = 22)。对活检组织进行以下一项或多项研究:通过被动僵硬度测量确定总僵硬度、胶原蛋白依赖性僵硬度和肌联蛋白依赖性僵硬度(差异提取分析)、胶原蛋白分析(生物化学或组织学)或肌联蛋白异构体及磷酸化分析。与对照组相比,HTN(-)HFpEF患者的左心室舒张末期压力、心肌被动僵硬度、胶原蛋白或肌联蛋白磷酸化无变化,但炎症生物标志物(C反应蛋白、可溶性ST2、金属蛋白酶组织抑制剂1)增加。与对照组和HTN(-)HFpEF组相比,HTN(+)HFpEF患者的左心室舒张末期压力、左心房容积、脑钠肽N末端前体肽、总僵硬度、胶原蛋白依赖性僵硬度和肌联蛋白依赖性僵硬度、不溶性胶原蛋白增加,PEVK S11878(S26)位点的肌联蛋白磷酸化增加,N2B S4185(S469)位点的磷酸化减少,炎症生物标志物增加。
无HFpEF的高血压不会改变被动心肌僵硬度。HTN(+)HFpEF患者的被动心肌僵硬度显著增加;胶原蛋白依赖性僵硬度和肌联蛋白依赖性僵硬度增加。这些数据表明,HFpEF的发生取决于胶原蛋白和肌联蛋白稳态的变化。